Skip to content

Study · Animal study (in vivo) · mouse · 2017

8 results

Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.

Ye X, Qi J, Yu D, Wu Y, Zhu S, Li S, Wu Q, Ren G, Li D

Journal of diabetes and its complications21 Jan 2017Cited by 21 (Europe PMC)

PMID28143735 (opens in a new tab)DOI10.1016/j.jdiacomp.2017.01.008 (opens in a new tab)PepBankPUB-28143735
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In type 2 diabetic db/db mice, liraglutide significantly decreased fed blood glucose levels.

    In plain wordsIn mice with type 2 diabetes, liraglutide lowered blood glucose in the fed state.

    Peptide
    Liraglutide
    Outcome
    DecreaseFed blood glucose
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Results demonstrated that three proteins could significantly decrease the fed blood glucose levels of db/db mice.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, after 1 week of treatment fed blood glucose was significantly lower with liraglutide than with mFGF21 or insulin glargine.

    In plain wordsIn mice with type 2 diabetes, after 1 week liraglutide lowered fed blood glucose more than mFGF21 or insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseFed blood glucose after 1 week, liraglutide versus mFGF21 and insulin glargine
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Comparator
    mFGF21 and insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    After treatment for 1week, the fed blood glucose levels of db/db mice in liraglutide group were significantly lower than those in mFGF21 and insulin glargine groups.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, from 2 weeks of administration the long-lasting hypoglycemic effect of liraglutide was inferior to that of mFGF21.

    In plain wordsIn mice with type 2 diabetes, from week 2 the blood-glucose-lowering effect of liraglutide lasted less well than that of mFGF21.

    Peptide
    Liraglutide
    Outcome
    Not applicableLong-lasting hypoglycemic effect, liraglutide versus mFGF21
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Comparator
    mFGF21
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    However, after 2weeks of administration, the long-lasting hypoglycemic effect of mFGF21 was superior to liraglutide and insulin glargine up to the end of the experiments.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, mFGF21 reduced glycosylated hemoglobin more than liraglutide after 8 weeks of treatment.

    In plain wordsIn mice with type 2 diabetes, after 8 weeks mFGF21 lowered glycosylated hemoglobin more than liraglutide did.

    Peptide
    Liraglutide
    Outcome
    Not applicableGlycosylated hemoglobin, liraglutide versus mFGF21
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Comparator
    mFGF21
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Compared with liraglutide and insulin glargine, mFGF21 significantly reduced the glycosylated hemoglobin levels and improved the ability on glycemic control, insulin resistance, serum lipid and liver function states in db/db mice after 8weeks treatments.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, mFGF21 improved insulin resistance more than liraglutide after 8 weeks of treatment.

    In plain wordsIn mice with type 2 diabetes, after 8 weeks mFGF21 improved insulin resistance more than liraglutide did.

    Peptide
    Liraglutide
    Outcome
    Not applicableInsulin resistance, liraglutide versus mFGF21
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Comparator
    mFGF21
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Compared with liraglutide and insulin glargine, mFGF21 significantly reduced the glycosylated hemoglobin levels and improved the ability on glycemic control, insulin resistance, serum lipid and liver function states in db/db mice after 8weeks treatments.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, mFGF21 improved serum lipid states more than liraglutide after 8 weeks of treatment.

    In plain wordsIn mice with type 2 diabetes, after 8 weeks mFGF21 improved blood fats more than liraglutide did.

    Peptide
    Liraglutide
    Outcome
    Not applicableSerum lipid profile, liraglutide versus mFGF21
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Comparator
    mFGF21
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Compared with liraglutide and insulin glargine, mFGF21 significantly reduced the glycosylated hemoglobin levels and improved the ability on glycemic control, insulin resistance, serum lipid and liver function states in db/db mice after 8weeks treatments.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, mFGF21 improved liver function states more than liraglutide after 8 weeks of treatment.

    In plain wordsIn mice with type 2 diabetes, after 8 weeks mFGF21 improved liver function more than liraglutide did.

    Peptide
    Liraglutide
    Outcome
    Not applicableLiver function, liraglutide versus mFGF21
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Comparator
    mFGF21
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Compared with liraglutide and insulin glargine, mFGF21 significantly reduced the glycosylated hemoglobin levels and improved the ability on glycemic control, insulin resistance, serum lipid and liver function states in db/db mice after 8weeks treatments.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In db/db mice, liraglutide up-regulated the mRNA expression of GLUT-4.

    In plain wordsIn mice with type 2 diabetes, liraglutide raised the gene activity of GLUT-4, a glucose transporter.

    Peptide
    Liraglutide
    Outcome
    IncreaseHepatic GLUT-4 mRNA expression
    Study

    mousen: not reported in source

    db/db mice (type 2 diabetes)
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    25 nmol/kg/day · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    liraglutide and insulin glargine could only up-regulate the mRNA expression of GLUT-4.
    2 context sentences
    Summary · context
    In the current study, we aim to compare the long-term pharmacological efficacy of mFGF21 (an FGF21 analogue), liraglutide and insulin glargine in type 2 diabetic db/db mice.
    Summary · context
    Db/db mice were initially treated with three kinds of proteins (25nmol/kg/day) by subcutaneous injection once a day for 4weeks, then subsequently be treated with once every two days for next 4weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.